Intuitive Surgical, Inc. (NASDAQ:ISRG) Shares Sold by Central Pacific Bank Trust Division

Central Pacific Bank Trust Division decreased its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.6% during the 4th quarter, Holdings Channel reports. The fund owned 6,491 shares of the medical equipment provider’s stock after selling 172 shares during the quarter. Central Pacific Bank Trust Division’s holdings in Intuitive Surgical were worth $3,388,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Founders Financial Securities LLC grew its stake in Intuitive Surgical by 10.6% during the 2nd quarter. Founders Financial Securities LLC now owns 2,139 shares of the medical equipment provider’s stock worth $952,000 after buying an additional 205 shares during the last quarter. Simon Quick Advisors LLC grew its position in Intuitive Surgical by 10.6% in the 2nd quarter. Simon Quick Advisors LLC now owns 1,820 shares of the medical equipment provider’s stock valued at $810,000 after buying an additional 175 shares during the last quarter. Larson Financial Group LLC increased its stake in Intuitive Surgical by 104.3% in the 2nd quarter. Larson Financial Group LLC now owns 476 shares of the medical equipment provider’s stock valued at $212,000 after buying an additional 243 shares during the period. Belpointe Asset Management LLC lifted its stake in shares of Intuitive Surgical by 6.0% in the 2nd quarter. Belpointe Asset Management LLC now owns 2,697 shares of the medical equipment provider’s stock worth $1,200,000 after acquiring an additional 153 shares during the period. Finally, Stablepoint Partners LLC boosted its holdings in shares of Intuitive Surgical by 2.9% in the second quarter. Stablepoint Partners LLC now owns 5,256 shares of the medical equipment provider’s stock valued at $2,332,000 after acquiring an additional 146 shares in the last quarter. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Insider Activity at Intuitive Surgical

In other Intuitive Surgical news, EVP Brian Edward Miller sold 2,553 shares of the company’s stock in a transaction that occurred on Tuesday, October 22nd. The stock was sold at an average price of $515.00, for a total transaction of $1,314,795.00. Following the completion of the sale, the executive vice president now owns 7,066 shares of the company’s stock, valued at $3,638,990. This represents a 26.54 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Mark Brosius sold 2,128 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, October 22nd. The shares were sold at an average price of $515.00, for a total transaction of $1,095,920.00. Following the completion of the transaction, the senior vice president now directly owns 273 shares in the company, valued at approximately $140,595. This represents a 88.63 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 48,190 shares of company stock valued at $25,012,927. 0.90% of the stock is owned by corporate insiders.

Intuitive Surgical Trading Up 2.1 %

NASDAQ ISRG traded up $11.25 during trading on Friday, reaching $535.28. 504,698 shares of the company’s stock were exchanged, compared to its average volume of 701,740. The firm has a market capitalization of $190.66 billion, a PE ratio of 86.06, a P/E/G ratio of 5.31 and a beta of 1.38. Intuitive Surgical, Inc. has a fifty-two week low of $320.26 and a fifty-two week high of $556.23. The company’s fifty day simple moving average is $532.28 and its 200-day simple moving average is $489.92.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The business had revenue of $2.04 billion during the quarter, compared to analyst estimates of $2.01 billion. Equities analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several research firms have issued reports on ISRG. Robert W. Baird boosted their target price on Intuitive Surgical from $503.00 to $565.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Stifel Nicolaus raised their price objective on shares of Intuitive Surgical from $525.00 to $610.00 and gave the stock a “buy” rating in a research note on Thursday, December 5th. Leerink Partners raised their price target on Intuitive Surgical from $489.00 to $502.00 in a research report on Thursday, October 17th. Morgan Stanley upgraded Intuitive Surgical from an “equal weight” rating to an “overweight” rating and upped their price objective for the company from $522.00 to $650.00 in a research report on Monday, December 2nd. Finally, Royal Bank of Canada boosted their target price on shares of Intuitive Surgical from $525.00 to $555.00 and gave the company an “outperform” rating in a research note on Friday, October 18th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and fifteen have issued a buy rating to the stock. According to data from MarketBeat.com, Intuitive Surgical has an average rating of “Moderate Buy” and a consensus price target of $554.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.